Enhancing Oral Anticancer Medication Safety Through an Interprofessional Competence and Consultation Model

Maryam Ali Alkahtani[1], Meshari Bashir Rabea Alrashidi[2], Ayedh Hadi Ayedh Alqahtani[3], Nawaf Sameer Hanidhal Al Mutairi[4]

[1]Consultant obstetrics and gynecology, [2]Pharmacist, [3]Radiology technologist, [4]Laboratory Technician
King Abdulaziz Medical City Riyadh,Ministry of National Guard

Abstract:
The advent of oral anticancer medications has revolutionized cancer treatment but introduced challenges in ensuring medication safety, adherence, and optimal outcomes. This paper proposes an interprofessional competence and consultation model to enhance medication safety for patients receiving oral anticancer therapies. Guided by implementation science frameworks, the model fosters interprofessional collaboration, implements robust medication therapy management processes, promotes patient-centered care and shared decision-making, and leverages continuous quality improvement strategies. Key components include comprehensive medication reconciliation, patient education, adherence monitoring, adverse effect management, and deprescribing. The model's implementation involves stakeholder engagement, workforce training, tailored strategies addressing barriers, and rigorous evaluation using mixed methods and the RE-AIM framework. While challenges like resistance to change and resource constraints are anticipated, the model represents a significant opportunity to improve medication safety, enhance patient outcomes, and optimize the delivery of oral anticancer therapies through a systematic, evidence-based approach.

INTRODUCTION:

The advent of oral anticancer medications has revolutionized cancer treatment, offering patients greater convenience, flexibility, and potential improvements in quality of life.

However, this shift from intravenous to oral administration has also introduced new challenges in ensuring medication safety, adherence, and optimal therapeutic outcomes.

Despite the advantages of oral anticancer therapies, their use is associated with unique risks, including complex dosing regimens, potential drug-drug interactions, and adverse effects that require close monitoring and management.

The transition to oral anticancer medications has highlighted the need for comprehensive support systems that address the multifaceted aspects of medication safety, patient education, and care coordination. Traditional healthcare models, often siloed and fragmented, may fail to provide the integrated, interprofessional approach necessary to address the complexities of oral anticancer therapy. This paper proposes the implementation of an interprofessional competence and consultation model to enhance medication safety and optimize outcomes for patients receiving oral anticancer treatments.

Rationale and Background:

Medication errors and adverse events related to oral anticancer therapies are well-documented and pose significant risks to patient safety and treatment outcomes (Weingart et al., 2018; Zerillo et al., 2018). Several factors contribute to these challenges, including inadequate patient education, lack of adherence monitoring, limited coordination among healthcare providers, and insufficient systems for identifying and managing drug-related problems (Schlichtig et al., 2019).

Furthermore, the growing complexity of cancer treatment regimens, involving multiple medications and

potential interactions, exacerbates the risk of medication errors and adverse events (Weingart et al., 2008). Patients receiving oral anticancer therapies often navigate their treatment journey without the same level of oversight and support typically provided in inpatient or infusion center settings.

The AMBORA (Arzneimitteltherapiesicherheit bei der Behandlung mit neuen oralen Antitumorwirkstoffen) study, a landmark randomized controlled trial conducted in Germany, demonstrated the significant benefits of an enhanced medication therapy management program for patients receiving oral anticancer agents (Dürr et al., 2019). The study's intervention, which included comprehensive patient education, medication reconciliation, and close monitoring by an interprofessional team, led to improved medication safety, increased patient knowledge, and better quality of life.

Building upon the success of the AMBORA study and recognizing the pressing need for safer and more effective delivery of oral anticancer therapies, this paper proposes the implementation of an interprofessional competence and consultation model. This model aims to establish a collaborative, patient-centered framework that leverages the expertise of various healthcare professionals, including oncologists, pharmacists, nurses, and other specialists, to optimize medication safety and patient outcomes.

Implementation Science Framework:

The proposed interprofessional competence and consultation model will be guided by the principles of implementation science, a discipline that aims to bridge the gap between research evidence and real-world practice (Bauer et al., 2015; Theobald et al., 2018).

Implementation science provides a systematic approach to translating evidence-based interventions into routine clinical care, addressing the complexities of healthcare systems and ensuring sustainable adoption and integration of effective practices.

The implementation process will be guided by well-established frameworks, such as the Consolidated Framework for Implementation Research (CFIR) (Damschroder et al., 2009) and the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework (Glasgow et al., 2019). These frameworks will inform the systematic planning, execution, and evaluation of the interprofessional competence and consultation model, ensuring a comprehensive and evidence-based approach.

Key Components of the Interprofessional Competence and Consultation Model:

The interprofessional competence and consultation model will encompass the following core components:

1.   Interprofessional Collaboration and Care Coordination:

The model will foster seamless collaboration among oncologists, pharmacists,

nurses, and other healthcare professionals involved in the care of patients receiving oral anticancer therapies. Structured interprofessional communication channels, such as regular case conferences, shared electronic health records, and standardized documentation protocols, will facilitate the exchange of critical patient information and treatment plans.

Collaborative practice agreements between physicians and pharmacists will enable pharmacists to assume an expanded role in medication management, including medication therapy reviews, dosage adjustments, and monitoring for drug-drug interactions and adverse effects (Holle et al., 2019; Vulaj et al., 2018).

2.   Comprehensive Medication Therapy Management:

Building upon the principles of the AMBORA study, the model will incorporate a robust medication therapy management program tailored to the unique needs of patients receiving oral anticancer treatments. This program will encompass the following key elements:

a. Medication Reconciliation: A thorough medication reconciliation process will be implemented at various transitions of care, ensuring accurate and up-to-date medication lists and identifying potential drug-related problems.

b. Patient Education and Counseling: Standardized educational materials and counseling sessions will be provided to patients and caregivers, addressing topics such as medication administration, adherence strategies, potential adverse effects, and when to seek medical attention.

c. Adherence Monitoring: Utilizing a combination of patient self-reporting, medication adherence technologies (e.g., pill boxes, mobile apps), and regular follow-up assessments,

the model will facilitate close monitoring of medication adherence and timely interventions when non-adherence is detected.

d. Adverse Effect Management: A structured approach to monitoring and managing adverse effects will be implemented, leveraging patient-reported outcome measures (e.g., PRO-

CTCAE) and evidence-based algorithms for dose adjustments and supportive care interventions.

e. Deprescribing and Medication Review: Regular medication reviews will be conducted to evaluate the continued necessity and appropriateness of oral anticancer therapies, as well as any concomitant medications, with a focus on deprescribing unnecessary or potentially

harmful drugs.

3. Patient-Centered Care and Shared Decision-Making:

The interprofessional competence and consultation model will emphasize patient- centered care and shared decision-making throughout the treatment journey.

Patients and caregivers will be actively engaged in treatment decisions, goal-setting, and self-management strategies. Their preferences, values, and lived experiences will be incorporated into the development of personalized care plans.

The model will leverage digital health technologies, such as patient portals, virtual consultations, and mobile applications, to facilitate convenient access to healthcare

providers, enhance communication, and promote patient empowerment and self-efficacy.

4. Quality Improvement and Continuous Monitoring:

Ongoing quality improvement efforts and continuous monitoring of key performance indicators will be integral to the model's implementation and sustainability.

Standardized metrics, such as medication adherence rates, patient-reported outcomes, and process measures (e.g., medication reconciliation completeness, adverse event reporting), will be routinely evaluated to identify areas for

improvement and inform iterative refinements to the model.

Regular audits and root cause analyses of medication-related incidents will be conducted, fostering a culture of continuous learning and process improvement within the

interprofessional team.

Implementation Strategy and Evaluation:

The implementation of the interprofessional competence and consultation model will follow a systematic and evidence-based approach, guided by implementation science frameworks and strategies. The implementation process will involve the following key steps:

1. Stakeholder Engagement and Needs Assessment:

Early engagement with key stakeholders, including healthcare providers, patients, caregivers, and policymakers, will be crucial to understand their perspectives, identify potential barriers and facilitators, and tailor the implementation strategy accordingly. A comprehensive needs assessment will be conducted to evaluate the

current state of oral anticancer medication management, identify gaps, and prioritize areas for improvement.

2. Intervention Adaptation and Contextualization:

Based on the findings from the needs assessment and stakeholder engagement, the interprofessional competence and consultation model will be adapted and

contextualized to align with the specific clinical settings, healthcare system

structures, and patient populations. This process will ensure the model's relevance, feasibility, and cultural appropriateness.

3. Workforce Training and Capacity Building:

Comprehensive training programs will be developed to equip healthcare

professionals with the knowledge and skills necessary to effectively implement the interprofessional competence and consultation model. This will include

interprofessional education, competency-based training modules, and ongoing mentorship and support.

4. Implementation Facilitation and Tailored Strategies:

Drawing upon the Expert Recommendations for Implementing Change (ERIC) compilation (Waltz et al., 2015) and the Consolidated Framework for

Implementation Research (CFIR) (Damschroder et al., 2009), tailored implementation strategies will be developed to address identified barriers and leverage facilitators.

These strategies may include audit and feedback mechanisms, clinical decision support systems, facilitation by implementation champions, and the use of incentives or disincentives.

5.   Evaluation and Continuous Quality Improvement:

A robust evaluation plan will be developed to assess the implementation process, outcomes, and impact of the interprofessional competence and consultation model. This evaluation will encompass both formative and summative components, utilizing a mixed-methods approach that incorporates quantitative measures (e.g., medication adherence rates, patient-reported outcomes, healthcare utilization metrics) and qualitative data (e.g., stakeholder interviews, focus groups, direct observations).

The RE-AIM framework (Glasgow et al., 1999) will be employed to evaluate the model's reach, effectiveness, adoption, implementation, and maintenance, providing a comprehensive understanding of its impact and facilitating continuous quality improvement efforts.

Ethical Considerations and Stakeholder Engagement:

The implementation of the interprofessional competence and consultation model will prioritize ethical considerations and active stakeholder engagement throughout the process.

Informed consent procedures will be established to ensure patients and caregivers understand the model's goals, potential risks and benefits, and their rights to opt-out or withdraw from specific components.

Patient privacy and data security will be paramount, with robust protocols and safeguards implemented to protect sensitive health information in compliance with relevant regulations (e.g., HIPAA in the United States, GDPR in the European Union).

Stakeholder engagement will extend beyond the initial needs assessment and include ongoing collaboration with patient advocacy groups, professional organizations, and regulatory bodies. This collaborative approach will foster transparency, accountability, and the co-creation of sustainable solutions that align with stakeholder priorities and values.

Anticipated Challenges and Mitigation Strategies:

While the implementation of the interprofessional competence and consultation model holds great promise, several challenges can be anticipated, and proactive mitigation

strategies should be developed. These challenges may include:

1.   Resistance to Change and Adoption Barriers:

Implementing a new care delivery model often encounters resistance from

healthcare professionals accustomed to traditional practices. Change management strategies, such as effective communication, leadership support, and continuous professional development, will be employed to address adoption barriers and foster a culture of innovation and continuous improvement.

2.   Interprofessional Collaboration Challenges:

Overcoming siloed working environments and establishing effective interprofessional collaboration can be challenging due to factors such as role ambiguity, power

dynamics, and communication barriers. Comprehensive interprofessional education, clear role delineation, and the establishment of shared goals and accountability mechanisms will be essential to mitigate these challenges.

3.   Resource Constraints and Sustainability:

The successful implementation and sustainability of the interprofessional competence and consultation model will require dedicated resources, including funding, staffing, and infrastructure. Collaborative efforts with healthcare administrators, policymakers, and payers will be necessary to secure sustainable

funding streams and integrate the model into existing healthcare delivery systems.

4.   Health Equity and Access Disparities:

Ensuring equitable access to the interprofessional competence and consultation model across diverse patient populations and healthcare settings will be a priority. Targeted strategies, such as community outreach, culturally and linguistically appropriate services, and the leveraging of digital health technologies, will be employed to address potential access barriers and health disparities.

Despite these anticipated challenges, the implementation of the interprofessional competence and consultation model represents a significant opportunity to improve

medication safety, enhance patient outcomes, and optimize the delivery of oral anticancer therapies. Through

a systematic, evidence-based approach guided by implementation
science frameworks, and active stakeholder engagement, the model can be successfully integrated into routine clinical practice, ultimately improving the quality of care for patients with cancer.

CONCLUSION:

The emergence of oral anticancer therapies has transformed cancer treatment, offering patients increased convenience and potential improvements in quality of life. However, this shift has also introduced new challenges in ensuring medication safety, adherence, and optimal therapeutic outcomes. The interprofessional competence and consultation model proposed in this paper represents a comprehensive and evidence-based approach to addressing these challenges.

By fostering interprofessional collaboration, implementing robust medication therapy management processes, promoting patient-centered care and shared decision-making, and leveraging continuous quality improvement strategies, this model has the potential to
significantly enhance medication safety and improve outcomes for patients receiving oral anticancer treatments.

The successful implementation of the interprofessional competence and consultation model will require a systematic and evidence-based approach, guided by implementation science frameworks and active stakeholder engagement. Addressing anticipated challenges, such as resistance to change, interprofessional collaboration barriers, resource constraints, and health equity disparities, will be crucial for the model's long-term sustainability and impact.

By bridging the gap between research evidence and real-world practice, the interprofessional competence and consultation model represents a transformative paradigm shift in the delivery of oral anticancer therapies. Its implementation has the potential to set new standards for patient-centered, high-quality, and equitable cancer care, ultimately improving the lives of patients and their families affected by this devastating disease.

REFERENCES:

1. Bauer, M. S., & Kirchner, J. (2019). Implementation science: What is it and why should I care? Psychiatry Research, 283, Article 112376.
2. Damschroder, L. J., Aron, D. C., Keith, R. E., Kirsh, S. R., Alexander, J. A., & Lowery, J. C. (2009).
3. Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science. Implementation Science, 4(1), Article 50.
4. Dürr, P., Schlichtig, K., Kelz, C., Deutsch, B., Maas, R., Eckart, M. J., Wilke, J., Wagner, H., Wolff,
5. K., Preuß, C., Dörje, F., & Fromm, M. F. (2019). The randomized AMBORA trial: Impact of pharmacological/pharmaceutical care on medication safety and patient-reported outcomes
6. during treatment with new oral anticancer agents. Journal of Clinical Oncology, 39(18), 1983- 1994.
7. Glasgow, R. E., Harden, S. M., Gaglio, B., Rabin, B., Smith, M. L., Porter, G. C., Ory, M. G., & Estabrooks, P. A. (2019). RE-AIM planning and evaluation framework: Adapting to new
8. science and practice with a twenty-year review. Frontiers in Public Health, 7, Article 64.
9. Glasgow, R. E., Vogt, T. M., & Boles, S. M. (1999). Evaluating the public health impact of health promotion interventions: The RE-AIM framework. American Journal of Public Health, 89(9), 1322-1327.
10. Holle, L. M., Segal, E. M., & Jeffers, K. D. (2019). The expanding role of the oncology pharmacist. Pharmacy, 8(3), Article 130.
11. Schlichtig, K., Dürr, P., Dörje, F., & Fromm, M. F. (2019). New oral anti-cancer drugs and medication safety. Deutsches Ärzteblatt International, 116(46), 775-782.
12. Theobald, S., Brandes, N., Gyapong, M., El-Saharty, S., Proctor, E., Diaz, T., Wanji, S., Elloker, S., Raven, J., Elsey, H., Bharath-Kumar, U., Pelletier, D., Peters, D. H., & Taegtmeyer, M. (2018). Implementation research: New imperatives and opportunities in global health. The Lancet, 392(10160), 2214-2228.
13. Vulaj, V., Hough, S., Bedard, L., Farris, K., & Mackler, E. (2018). Oncology pharmacist

opportunities: Closing the gap in quality care. Journal of Oncology Practice, 14(6), e403- e411.

14. Waltz, T. J., Powell, B. J., Matthieu, M. M., Damschroder, L. J., Chinman, M. J., Smith, J. L., Proctor, E. K., & Kirchner, J. E. (2015). Use of concept mapping to characterize relationships among implementation strategies and assess their feasibility and importance: Results from the Expert Recommendations for Implementing Change (ERIC) study. Implementation

15. Science, 10, Article 109.

16. Weingart, S. N., Brown, E., Bach, P. B., Eng, K., Johnson, S. A., Kuzel, T. M., Langbaum, T. S.,

17. Leedy, R. D., Muller, R. J., Newcomer, L. N., O'Brien, S., Rabizadeh, S., Sauvigne, A., Walters, R. S., & Eisenberg, P. D. (2008). NCCN Task force report: Oral chemotherapy. Journal of the

18. National Comprehensive Cancer Network, 6(Suppl. 3), S1-S14.

19. Weingart, S. N., Zhang, L., Sweeney, M., & Hassett, M. (2018). Chemotherapy medication errors. The Lancet Oncology, 19(4), e191-e199.

20. Zerillo, J. A., Goldenberg, B. A., Kotecha, R. R., Tewari, A. K., Jacobson, J. O., & Krzyzanowska,

21. M. K. (2018). Interventions to improve oral chemotherapy safety and quality: A systematic review. JAMA Oncology, 4(1), 105-117.